Institut de cancérologie Lucien Neuwirth

corporate_fareorganization

Institut de cancérologie Lucien Neuwirth

- Funding / Projects
  (21)

21 Projects, page 1 of 5

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant
assignment_turned_inProjectPartners:HUS, Groupe Hospitalier Pitié Salpétrière, HUG, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Poitiers +10 partners
HUS,
Groupe Hospitalier Pitié Salpétrière,
HUG,
Hôpital Claude Huriez,
Centre Hospitalier Universitaire de Poitiers,
Centre Hospitalier Universitaire de Toulouse,
Centre Hospitalier Universitaire de Limoges,
Institut Paoli-Calmettes- (IPC),
CHRU MTP,
Hôpital Necker- Enfants malades,
HCL,
Institut de cancérologie Lucien Neuwirth,
CHU Nantes - Hôtel Dieu,
CHU,
Groupe Hospitalier Henri Mondor - Albert Chenevier
Funder: Institut National du Cancer Project Code: INCa-DGOS-11089
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Randomized phase III study of gemcitabine and cisplatin (GC) versus high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder
assignment_turned_inProjectPartners:Centre François Baclesse, Centre Léon Bérard, Institut Bergonié, Hôpital Saint-Louis, Institut Curie +6 partners
Centre François Baclesse,
Centre Léon Bérard,
Institut Bergonié,
Hôpital Saint-Louis,
Institut Curie,
Centre Hospitalier Universitaire de Rouen,
HUS,
Institut de cancérologie Lucien Neuwirth,
Institut Paoli-Calmettes- (IPC),
Institut Claudius Regaud,
Institut Gustave Roussy
Funder: Institut National du Cancer Project Code: INCa-DGOS-3712
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
ColoNav. Patients Navigator for colorectal screening. Intervention study in deprived areas
assignment_turned_inProject2012 - 2015Partners:LYON2, Institut Gustave Roussy, Centre Georges-François Leclerc, Institut de cancérologie Lucien Neuwirth
LYON2,
Institut Gustave Roussy,
Centre Georges-François Leclerc,
Institut de cancérologie Lucien Neuwirth
Funder: Institut National du Cancer Project Code: INCa-6029
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
AlkOx-NET: O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: predictive factor of response to alkylating agents and interest of oxaliplatin in patients with unmethylated MGMT NET. A randomized phase II study.
assignment_turned_inProjectPartners:ICM-VAL D'AURELLE, Hôpital privé Jean Mermoz, Institut de cancérologie Lucien Neuwirth, Centre Hospitalier Universitaire de Toulouse, Groupe Hospitalier Cochin +5 partners
ICM-VAL D'AURELLE,
Hôpital privé Jean Mermoz,
Institut de cancérologie Lucien Neuwirth,
Centre Hospitalier Universitaire de Toulouse,
Groupe Hospitalier Cochin,
HUS,
CHU Dijon-Bourgogne - Centre Hospitalier Universitaire de Dijon,
Centre Hospitalier Régional et Universitaire de Lille,
Hôpital Avicenne,
Hôpital Édouard Herriot
Funder: Institut National du Cancer Project Code: INCa-DGOS-11191
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
MOSCAR 01 - Multicenter randomized phase III study evaluating the efficacy and safety of systemic treatments of bone metastases from kidney cancer in patients treated with targeted therapies.
assignment_turned_inProjectPartners:Institut de cancérologie Lucien Neuwirth, Centre Jean Perrin, Centre Eugène Marquis, Centre René Gauducheau, ICM-VAL D'AURELLE +11 partners
Institut de cancérologie Lucien Neuwirth,
Centre Jean Perrin,
Centre Eugène Marquis,
Centre René Gauducheau,
ICM-VAL D'AURELLE,
Institut de Cancérologie de l'Ouest,
Centre Hospitalier Universitaire de Nîmes,
Centre Georges-François Leclerc,
Institut Gustave Roussy,
Institut Paoli-Calmettes- (IPC),
Centre Léon Bérard,
Institut Claudius Regaud,
Institut de Cancérologie de Lorraine,
Centre Oscar Lambret,
Hôpital Saint André,
Hôpital Européen Georges Pompidou (HEGP) - AP-HP
Funder: Institut National du Cancer Project Code: INCa-DGOS-11182
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
3
4
5
chevron_right

Institut de cancérologie Lucien Neuwirth

Institut de cancérologie Lucien Neuwirth

21 Projects, page 1 of 5

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

Randomized phase III study of gemcitabine and cisplatin (GC) versus high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder

ColoNav. Patients Navigator for colorectal screening. Intervention study in deprived areas

AlkOx-NET: O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: predictive factor of response to alkylating agents and interest of oxaliplatin in patients with unmethylated MGMT NET. A randomized phase II study.

MOSCAR 01 - Multicenter randomized phase III study evaluating the efficacy and safety of systemic treatments of bone metastases from kidney cancer in patients treated with targeted therapies.

Loading